Strategy

Nightingale Health’s strategy to build preventative healthcare is focused on two markets: corporate customers and the public sector. Private and public healthcare providers, diagnostic service providers, life insurance companies, specialized healthcare providers, and universities and research institutes conducting medical research all stand to benefit from Nightingale Health’s blood analysis technology. 

The core of Nightingale Health’s strategy is to provide a comprehensive solution as a foundation for a new operating logic and system for preventative healthcare. It does this by making its proprietary blood test widely available to different actors in the healthcare industry. Since the test only requires a single blood sample, it can be easily implemented and integrates seamlessly into existing sampling and reporting practices in healthcare. Nightingale Health’s blood test provides the tools to systematically detect disease risks, supporting targeted prevention of disease onset. Because the blood test is objective and easily repeatable – unlike other risk calculators used in healthcare today – the effectiveness of different interventions can be monitored with retesting at both the individual and population levels, enabling the redirection of funding toward operating models that most effectively reduce risks.

Disease risk detection in healthcare today is manual and slow, which is why current methods are not adequate for detecting risks or tracking risk progression at the population level. Nightingale Health’s proprietary test, based on a single blood sample, is a superior solution in the wide-scale detection of disease risks and tracking risk progression. It can be used to replace many tests and risk predictions conducted in healthcare today and begin to systematically detect risks for everyone. Nightingale Health’s blood test identifies common chronic disease risks from a single blood sample, all at once. Because the test only requires one blood sample, it can be used to assess population-level disease risks without burdening healthcare’s already limited resources. A clear results report makes it easy for healthcare professionals to communicate disease risks and recommend actions to patients. Objective and repeatable risk detection enables the monitoring of intervention effectiveness and the allocation of resources and funding to those models that most effectively reduce disease risk. 

Nightingale Health’s blood test is key to building a preventative healthcare system. The better we understand the disease risks of the future, the better we can target and fund preventative measures and reduce the number of sick people in the future.

Nightingale Health’s business target for the financial year 2025–2026 is:

• Increase revenue by at least 50% compared to the previous financial year

• To conclude an agreement to analyze two million samples annually in Europe
• To conclude an agreement to analyze ten million samples annually in the United States or in Asia
• To extend laboratory capacity in respective geographical areas to meet the analysis capacity required by the aforementioned agreements
• To achieve positive EBITDA 

• To analyze 100 million blood samples from partnerships with the healthcare sector, health initiatives, and white label partners
• To generate EUR 500 million in annual revenue from partnerships with the healthcare sector, health initiatives, and white label partners